AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Shlomo Kramer: “The Palo Alto-CyberArk acquisition is the end of a successful run from PANW”
2
Intel to slash key manufacturing and engineering roles
3
Palo Alto CEO on $25B CyberArk deal: “This is the lowest our stock will be for the next five years”
4
Palo Alto closing on over $20 billion acquisition of CyberArk
5
Noma Security raises $100 million to defend against AI agent vulnerabilities
More news

Therapix

4 stories about Therapix
חממת גידול קנאביס בבריטניה

Cannabis Companies Therapix and Destiny to Merge

28.07.19|Adi Pick
The merged company will focus on Therapix's technology and assets pertaining to clinical-stage pharmaceutical applications of cannabis, and will include Destiny's genomics-based cannabis breeding techniques and development capabilities
מריחואנה קנאביס גראס 2

Cannabis Company Therapix Biosciences to Raise $2.25 Million in Direct Offering

28.03.19|Lilach Baumer
In December, Israel-based Therapix scrapped a deal to be acquired by Canadian FSD Pharma for $48 million worth of FSD stock
ד"ר ראזה בוקארי יו"ר משותף ומנכ"ל FSD פארמה

FSD Pharma’s Acquisition of Therapix Hits a Snag

12.12.18|Tzally Greenberg
In October, FSD agreed to buy Therapix for $48 million in stock, but a Tuesday filing by Therapix revealed that the companies have returned to the negotiating table
ד"ר ראזה בוקארי יו"ר משותף ומנכ"ל FSD פארמה

FSD Pharma Co-Chairman on Where the Cannabis Industry Is Headed

28.11.18|Tzally Greenberg
On a visit to Israel, the co-chairman of the company said he believes cannabis research is going to come from Israel and Australia. He expects China to become a significant player in the cannabis market